← All publications

New ACC research: combo drugs & a radiotherapy trial ๐Ÿฉบ

Here is what is new for adrenocortical carcinoma. ๐Ÿ’Š AKT and MEK combo study Researchers found that blocking two growth signals, AKT and MEK, works better than either alone. They tested the drugs capivasertib and cobimetinib in patient-derived models. This suggests a new systemic option for patients who need more than standard care. ๐Ÿ“„ Adrenal procedure review A new paper reviews how doctors use biopsies and ablation for adrenal masses. It explains when these tools help diagnose or treat limited metastases. This is useful context for understanding your care options beyond surgery. ๐Ÿ“Š Radiotherapy trial in China A trial run by Sun Yat-sen University (China) is testing adjuvant radiotherapy after surgery. It aims to see if radiation reduces the chance of the cancer returning in high-risk patients. The study is not yet recruiting, with an expected start date of September 15, 2025. #AdrenocorticalCarcinoma #ACC #CancerResearch #PatientSupport AI-generated; for informational purposes only, not medical advice

Cover image: adrenal cortex carcinoma - new trials and research, Oct 31 to Nov 7, 2026